Turkulainen Faron hakee syöpälääkkeelleen myyntilupaa Yhdysvaltojen markkinoille ts.fi/uutiset/605368…

Great news!

Now out. We discovered novel STAB1 mutations that cause loss of protein in patients with hyperferritinemia. InFLAMES Flagship Turun yliopisto - University of Turku A form of inherited hyperferritinemia associated with bi-allelic patho... sciencedirect.com/science/articl…

Makrofagiin kohdennetuista syöpähoidoista kiinnostuneille:

This is my last day as an Academy Research Fellow. Looking back at the five years with secured funding: 35 co-authored publications, 2 supervised PhDs, 2 clinical trials and 4 patent applications. I can say I did the money justice Suomen Akatemia | Research Council of Finland InFLAMES Flagship Turun yliopisto - University of Turku

"Koehenkilöitä on jonoksi asti" – Maija Hollmén työryhmineen Turussa tutkii ainutlaatuista lääkettä, joka näyttää tehoavan toivottomaan leukemiaan ts.fi/teemat/6134648…

Amazing study by Biswas Lab_TMC-ACTREC et al. in Immunity Shorter version here in preview 👉🏻Dimeric IgA specifically disables intracellular mutated oncodrivers: Immunity cell.com/immunity/fullt…

Find our Preview in the latest issue of Immunity describing a potential game changer in cancer immunotherapy InFLAMES Flagship MediCity Research Laboratory Turun yliopisto - University of Turku

And here is the next one. A great effort from many people and Faron Pharmaceuticals Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial: Cell Reports Medicine cell.com/cell-reports-m…

Happy to have contributed a small part to this exceptional study by HRUH hematology now online in Immunity Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers: Immunity cell.com/immunity/fullt…

Nöyrimmät kiitokset tuesta ❤️ Sigrid Jusélius Stiftelse

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors - check out this first-in-human MATINS trial conducted by Petri Bono, Hollmén lab & others in @cellrepmed #AACR24 hubs.li/Q02rwZWZ0

We voted for the Popular Prize of the European Inventor Award 2024 finalist #bexmarilimab Faron Pharmaceuticals InFLAMES Flagship Turun yliopisto - University of Turku MediCity Research Laboratory a.cstmapp.com/gallery/973466…

The pioneers of Finnish Biotech. Could not be prouder of my parents🩷

Check out our review on the clinical landscape of macrophage-reprogramming cancer immunotherapies (700 clinical trials with almost 200 therapeutics) and stay updated with the latest advancements in the field. #CancerResearch #ImmunotherapyBreakthroughs nature.com/articles/s4141…

Glad to co-chair with Guillaume Jacquemet the special ECR Council session on #eacr2024 EACR Terrific talks and clinical relevant data #macrophages #CRC #melanoma #Myeloidcells Hollmén lab Giovanni Germano Berta LSL Casanova Acebes Lab CNIO Stop Cancer TurkuBioscience Università di Torino